January 2009 Volume 9 Number 1
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=37&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Cancer online. To purchase a subscription,
please visit: http://links.ealert.nature.com/ctt?kn=44&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=67&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cancer Impact Factor: 29.19 *
(*Journal Citation Reports, Thomson, 2007)
*********************************************************************
=========================== ADVERTISEMENT ===========================
IT'S NOW FREE TO POST YOUR VACANCY ON
naturejobs.com http://links.ealert.nature.com/ctt?kn=61&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
It's the breakthrough you've been waiting for. Naturejobs.com -
the scientific jobs board from Nature -
now lets you advertise your vacancy completely FREE OF CHARGE
Go to http://links.ealert.nature.com/ctt?kn=70&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0 or telephone:
Europe: +44 (0) 20 78434961
US: + 1 800 9897718
=====================================================================
=========================== ADVERTISEMENT ===========================
Cell Death & Differentiation...something special going on at http://links.ealert.nature.com/ctt?kn=53&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0.
Cell Death & Differentiation publishes a select number of Special Issues that comprise reviews dedicated to the understanding of specific areas in cell death. Past special issues include: Immunity; Hypoxia; Tumor Stress, Cell Death and the Ensuing Response. Each Special Issue offers a select number of articles free for your viewing. Get the latest Special Issue online at http://links.ealert.nature.com/ctt?kn=53&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
=====================================================================
This month's FEATURED article:
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang, Priscilla L. Yang and Nathanael S. Gray
p28 | doi:10.1038/nrc2559
http://links.ealert.nature.com/ctt?kn=65&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
=====================================================================
From the editors
p1 | doi:10.1038/nrc2581
http://links.ealert.nature.com/ctt?kn=57&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Metastasis: Moved to act
p3 | doi:10.1038/nrc2564
http://links.ealert.nature.com/ctt?kn=64&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Oncogenesis: It's all about translation
p4 | doi:10.1038/nrc2565
http://links.ealert.nature.com/ctt?kn=80&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Tumorigenesis: Can you have too much MYC?
p4 | doi:10.1038/nrc2578
http://links.ealert.nature.com/ctt?kn=82&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Tumorigenesis: An end to the unSIRTainty?
p5 | doi:10.1038/nrc2569
http://links.ealert.nature.com/ctt?kn=13&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Cancer stem cells: Common as muck
p6 | doi:10.1038/nrc2563
http://links.ealert.nature.com/ctt?kn=31&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Metastasis: Maintaining group polarity
p6 | doi:10.1038/nrc2573
http://links.ealert.nature.com/ctt?kn=86&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
IN BRIEF
Microrna | Tumorigenesis | Leukaemia | Tumour suppressors
p7 | doi:10.1038/nrc2574
http://links.ealert.nature.com/ctt?kn=41&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Proteomics: Insider information
p8 | doi:10.1038/nrc2567
http://links.ealert.nature.com/ctt?kn=54&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Biomarkers: Decoding the microvesicle message
p8 | doi:10.1038/nrc2572
http://links.ealert.nature.com/ctt?kn=43&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
IN THE NEWS
The regression question
p8 | doi:10.1038/nrc2575
http://links.ealert.nature.com/ctt?kn=32&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
TECHNOLOGY WATCH
Improving cancer cell imaging
p9 | doi:10.1038/nrc2580
http://links.ealert.nature.com/ctt?kn=19&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Angiogenesis: Renaissance molecule
p10 | doi:10.1038/nrc2568
http://links.ealert.nature.com/ctt?kn=2&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Cell polarity: Morphogenesis is the key
p10 | doi:10.1038/nrc2576
http://links.ealert.nature.com/ctt?kn=58&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Genomics: Distinguishing drivers from passengers
p11 | doi:10.1038/nrc2566
http://links.ealert.nature.com/ctt?kn=26&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Signalling: ERBB2 hangs in the balance
p12 | doi:10.1038/nrc2570
http://links.ealert.nature.com/ctt?kn=75&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Cytoskeleton: Invading forces
p12 | doi:10.1038/nrc2579
http://links.ealert.nature.com/ctt?kn=49&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Metabolism: Room to breathe
p13 | doi:10.1038/nrc2577
http://links.ealert.nature.com/ctt?kn=5&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
The biology of Hodgkin's lymphoma
Ralf Kuppers
p15 | doi:10.1038/nrc2542
Hodgkin's lymphoma is a unique B-cell malignancy. This Review discusses
the aetiology and genetics of this disease and its distinguishing features.
Abstract: http://links.ealert.nature.com/ctt?kn=89&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=46&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang, Priscilla L. Yang and Nathanael S. Gray
p28 | doi:10.1038/nrc2559
Inhibition of kinase activity has received enormous interest as a therapeutic
strategy for cancer. This Review discusses the current approaches to develop
and characterize new inhibitors.
Abstract: http://links.ealert.nature.com/ctt?kn=77&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=65&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Tetraspanins: push and pull in suppressing and promoting metastasis
Margot Zoller
p40 | doi:10.1038/nrc2543
Tetraspanins have only recently received attention as both metastasis
suppressors and metastasis promoters. The ability of these proteins to
collect a variety of molecules associated with tumour progression or tumour
suppression in membrane microdomains might explain their multifaceted
functions in metastasis.
Abstract: http://links.ealert.nature.com/ctt?kn=55&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Toll-like receptors and cancer
Seth Rakoff-Nahoum and Ruslan Medzhitov
p57 | doi:10.1038/nrc2541
The development of cancer has been associated with microbial infection,
injury, inflammation and tissue repair. This Perspective discusses how
the function of the Toll-like receptors may relate to these processes
in the context of carcinogenesis.
Abstract: http://links.ealert.nature.com/ctt?kn=28&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=47&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
OPINION
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic
class for cancer
David H. Kirn and Steve H. Thorne
p64 | doi:10.1038/nrc2545
A new therapeutic class of oncolytic poxviruses has recently been developed
that combines targeted and armed approaches for treating cancer. Using
vaccinia virus as an example, this Perspective describes their mechanisms
of action and promising clinical results.
Abstract: http://links.ealert.nature.com/ctt?kn=63&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=90&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
The American Journal of Gastroenterology (AJG) is coming to Nature Publishing Group with a new look and new features in 2009
Ranked the #1 clinical journal covering gastroenterology and hepatology, AJG provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients.
Be among the first to preview AJG's new look. Register today to receive a free copy in January: http://links.ealert.nature.com/ctt?kn=6&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=33&m=30766548&r=MTQ3NDAzMjc3NQS2&b=2&j=NDQzNDA5NTIS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
